# US 2026/0060970 A1 · Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060970 A1
- Document ID: US20260060970A1
- Status: Published application
- Kind: A1
- Application number: 19/103,774
- Filed: 2023-08-16
- Published: 2026-03-05
- Earliest claimed: 2022-08-18
- Assignees: Mitodicure GmbH
- Applicants: Mitodicure GmbH
- Inventors: Klaus WIRTH
- Web page: https://patentgrep.com/patent/US20260060970A1

## CPC

- A61K 31/527: spiro-condensed
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/4162: condensed with heterocyclic ring systems
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 31/12: Antivirals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The instant invention relates to the use of a substance with phosphodiesterase-7 inhibitory activity (PDE7 inhibitor) as active ingredient in a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of different diseases, syndromes, disease states, or conditions associated with chronic fatigue, exhaustion and/or exertional intolerance using PDE7 inhibitors alone or in combination with other therapeutic agents.

## Claims

### Claim 1

Substance with phosphodiesterase-7 inhibitory activity (PDE7 inhibitors) for use as active ingredient in a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of chronic fatigue, exhaustion and/or exertional intolerance and for the treatment and prevention of diseases that are associated with chronic fatigue, exhaustion and/or exertional intolerance.

### Claim 2 (depends on 1)

Substance as claimed in claim 1, wherein diseases that are associated with chronic fatigue, exhaustion and/or exertional intolerance are diseases diagnosed as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), systemic exertional intolerance, exertional intolerance, Long COVID complaints, post-Covid-19 syndrome (PCS), post-acute Covid syndrome (PACS), Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), post-vaccination syndrome (post-vac-syndrome) after COVID-19 vaccinations (Long Vax) and vaccinations against other germs, virus and pathogenic agents, and postinfectious fatigue after viral, bacterial, or fungal infections, in particular ME/CFS of non-infectious, non-inflammatory and non-immunological cause.

### Claim 3 (depends on 1)

Substance as claimed in claim 1, wherein chronic fatigue and exhaustion are symptoms of or are associated with cancer (cancer-related fatigue), fibromyalgia, Ehlers-Danlos syndrome, Marfan syndrome, Gulf War illness, the autoimmune diseases Rheumatoid Arthritis, ANCA vasculitis and Sjögren's syndrome, and other autoimmune diseases with fatigue and exhaustion as debilitating symptoms.

### Claim 4 (depends on 1, 2, 3)

The substance as claimed in one or more of claims 1 to 3, wherein the PDE7 inhibitory material is a material that inhibits the enzymatic activity of PDE7 (PDE7A, PDE7B, or PDE7A and PDE7B) at an IC50<50 μM, preferably at an IC50≤1 μM, more preferred at an IC50 of from 0.1 to 600 nM, in particular preferred at an IC50 of from about 0.2 to about 100 nM, and further in particular preferred at an IC50 of from about 1 to about 100 nM.

### Claim 5 (depends on 1, 2, 3)

The substance as claimed in one or more of claims 1 to 3, wherein the PDE7 inhibitory material is a material that inhibits the enzymatic activity of PDE7A, preferably the PDE7 inhibitory material is a material that inhibits the enzymatic activity of PDE7A at an IC50<50 μM, preferably at an IC50≤1 μM, more preferred at an IC50 of from 0.1 to 600 nM, in particular preferred at an IC50 of from about 0.2 to about 100 nM, and further in particular preferred at an IC50 of from about 1 to about 100 nM.

### Claim 6 (depends on 1, 2, 3, 4)

The substance as claimed in one or more of claims 1, 2, 3, 4, and 5, wherein the PDE7 inhibitory agent stimulates the Na+/K+-ATPase and the NCLX in skeletal muscle and improves blood flow to skeletal muscles and brain by raising cAMP.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The substance as claimed in one or more of claims 1 to 6, wherein the PDE7 inhibitory agent is present in a pharmaceutical preparation, preferably in the form of an oral drug, intravenous, subcutaneous, intramuscular, pharyngeal, and nasal administration.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The substance as claimed in one or more of claims 1 to 7, wherein the PDE7 inhibitory agent is a chemical compound, a protein or polypeptide, a nucleic acid molecule, ribozyme, DNAzyme, a protein degrader, or a material for gene therapy.

### Claim 9 (depends on 8)

The substance as claimed in claim 8, wherein the chemical compound is a small molecule inhibitor including natural and synthetic substances that have a low molecular weight, such as, a peptide, a peptidomimetic and a non-peptide inhibitor such as a classical small molecule chemical compound, preferably the small molecule inhibitor having a molecular weight of less than about 750 g/mol and an IC50 for inhibiting PDE7 (PDE7A, PDE7B, or PDE7A and PDE7B) at an IC50<50 μM, preferably at an IC50≤1 μM, more preferred at an IC50 of from 0.1 to 600 nM, in particular preferred at an IC50 of from about 0.2 to about 100 nM, and further in particular preferred at an IC50 of from about 1 to about 100 nM.

### Claim 10 (depends on 8)

The substance as claimed in claim 8, wherein the chemical compound is a small molecule inhibitor including natural and synthetic substances that have a low molecular weight, such as, a peptide, a peptidomimetic and a non-peptide inhibitor such as a classical small molecule chemical compound, preferably the small molecule inhibitor having a molecular weight of less than about 750 g/mol and wherein the PDE7 inhibitory material is a material that inhibits the enzymatic activity of PDE7A, preferably the PDE7 inhibitory material is a material that inhibits the enzymatic activity of PDE7A at an IC50<50 μM, preferably at an IC50≤1 μM, more preferred at an IC50 of from 0.1 to 600 nM, in particular preferred at an IC50 of from about 0.2 to about 100 nM, and further in particular preferred at an IC50 of from about 1 to about 100 nM.

### Claim 11 (depends on 8)

The substance as claimed in claim 8, wherein the PDE7 inhibitory agent is a protein or polypeptide including a PDE7-binding antibody, nanobody, or functionally related protein or protein fragment or fusion protein, including a single-chain variable fragment or a designed ankyrin repeat protein or lipocalin/anticalin.

### Claim 12 (depends on 8)

The substance as claimed in claim 8, wherein the PDE7 inhibitory agent inhibits PDE7 expression and is an antisense nucleic acid molecule such as antisense oligonucleotide, antisense RNA, antisense mRNA, antisense DNA, or a PDE7 RNAi molecule, siRNA, microRNA or other such molecule, or a PDE7 altering ribozyme, or a PDE7 altering DNAzyme.

### Claim 13 (depends on 8)

The substance as claimed in claim 8, wherein the PDE7 inhibitory agent is a protein degrader, like a PROTAC, SNIPER, HaloPROTAC, HyT, LYTAC, AUTAC, ATTEC, RIBOTEC, monomeric degrader, double-mechanism degrader, SARD, TF-PROTAC, dual-PROTAC, SERD, bispecific aptamer chimera, AbTAC, GlueTAC, AUTOTAC, CMA-based degrader, MADTAC, ATAC, molecular glue, biodegraders, mRNA for the biodegrader protein, mRNA for the biodegrader protein in a lipid nanoparticle formulation, all targeted at PDE7.

### Claim 14 (depends on 8)

The substance as claimed in claim 8, wherein the PDE7 inhibitory agent is a gene therapy modifying, completing, replacing, or deleting PDE7 genes.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The substance as claimed in one or more of claims 1 to 14, wherein the PDE7 inhibitory agent is a member selected from the group consisting of substances containing the structural units pyrazolopyrimidinone, spirocycle, spirocyclic quinazoline, 8′-chloro-2′,3′-dihydro-2′-oxospiro[cyclohexane-1,4′(1′H)-quinazolin]-5′-yl, thiadiazole and oxadiazole, pyridinylpyrazolopyrimidinone, arylindenopyridine, thienopyrazole, 3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide, 3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-thieno[2,3-c]pyrazole-5-carboxamide, imidazotriazinone, benzenesulfonamide, thiazol-2-yl-imine, (4,2-disubstituted-thiazol-5-yl)amine, amine-substituted thiopheno[2,3-d]pyrimidine, nitrogen-containing bicycles, 4-substituted fused heteropyrimidine and fused hetero-4-pyrimidone, 2-amine-substituted quinazoline and pyrido[2,3-d]pyrimidine, purine, amine-substituted pyrimidine, amine-substituted purine, fused heterocycles containing a 2-amine-substituted pyrimidine, phthalazinone, 3,4-dihydroisoquinoline and isoquinoline, 1-phenyl-derivative-substituted 3,4-dihydroisoquinoline, sulphonamide, heterobiaryl sulphonamide, naphthalenyl of dihydropurin-6-one, spirocondensed quinazolin-2-one, spirocyclic and substituted quinazoline, imidazotriazine, spirocondensed 4-amino-butanecarboxylic adic, 4-amine-substituted thieno[2,3-d]pyrimidine-6-carbonitrile, pyrimidin-2-yl sulfide, 5-oxo-pyrrole-3-carboxylate, thieno[2,3-b]thiophen-3-amine, indolo[2,3-b]quinoxaline, methylphenanthrene, spirocyclic and 5,8-substituted (1H,3H)-quinazoline, pyrrolopyrimidine, imidazole, isoxazole, 4-cyano-1H-pyrrole-2-carboxylate, imidazo[4,5-c]pyridine, quinazoline, 3-substituted 2,3-dihydro-2-thioxo-4(1H)-quinazolinone and 3-substituted 2,3-dihydro-2-oxo-4(1H)-quinazolinone, 3-substituted 2,3-dihydro-2-thioxothieno[3,2-d]pyrimidin-4(1H)-one, 3-substituted 2,3-dihydro-2-thioxo[1]benzothieno[3,2-d]pyrimidin-4(1H)-one, ethyl-substituted purine-2-amine, quinazolinedione, bicyclic nitrogen-containing heterocycles substituted with an amino group, 3,5-substituted 1,2,3-triazolo[4,5-d]pyrimidin-7-amine, bicyclic 3-substituted 1,2,4-triazole, 2-pyrimindinone, isochromenone, 5-imino-1,2,4-thiadiazole, 4,5-dihydroisoxazole-substituted pyrazolopyrimidine, imidazopyridine, dihydropurine, pyrrole, benzothiopyranoimidazolone, guanine, arylindenopyrimidine, sulfonylbenzene, trans-aconitic acid, thienopyrimidine/thienopyrimidinone, 2-(isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one, isothiazole and isoxazole fused pyrimidone, imidazopyridazinone, sulfide, steroids, podocarpanes, fused thiophenes, dihydronaphthyridinedione, furan, S-substituted quinazolines, methylxanthine, and benzothienothiadiazine.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The substance as claimed in one or more of claims 1 to 15, wherein the inhibitory agent is a member selected from the group consisting of compounds with the CAS Registry Numbers assigned by the Chemical Abstracts Service (CAS) of 553669-13-9, 553668-77-2, 460346-28-5, 756535-34-9, 873540-36-4, 873537-95-2, 873538-20-6, 873538-81-9, 873541-44-7, 873541-70-9, 873541-14-1, 873541-04-9, 433695-36-4, 1086424-30-7, 16081-93-9, 1062094-00-1, 1062094-26-1, 873541-45-8, 908570-13-8, 908570-12-7, 873541-45-8 (·H2O), 906079-12-7, 1041846-43-8, 1374784-19-6, 1041846-46-1, 1140589-61-2, 1140589-71-4, 1140589-76-9, 1140590-16-4, 1162649-94-6, 1162650-34-1, 1140590-71-1, 1162650-04-5, 1162650-22-7, 1162650-24-9, 1251701-48-0, 1251701-62-8, 1251702-51-8, 1251702-23-4, 1251702-27-8, 1251701-58-2, 1251702-08-5, 1281681-33-1, 1281681-33-1 without 2 HBr, 58-32-2, 6493-05-6, 873539-34-5, 18741-24-7, and 28822-58-4.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A pharmaceutical composition, characterized in that it comprises at least one PDE7 inhibitory agent as claimed in one or more of claims 1 to 16.

### Claim 18 (depends on 9, 14, 16, 17)

The pharmaceutical composition as claimed in claim 17, characterized in that it comprises (i) at least one PDE7 inhibitory agent according to claim 9, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, polymorph, ester, ether, enantiomer, prodrug, or metabolite thereof, and at least one pharmaceutically acceptable diluent or excipient, or (ii) at least one compound of the formulas according to claim 14 or claim 16, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, polymorph, ester, ether, enantiomer, prodrug, or metabolite thereof, and at least one pharmaceutically acceptable diluent or excipient.

### Claim 19

Use of a compound with phosphodiesterase-7 inhibitory activity (PDE7 inhibitors) for the manufacture of a medicament for the treatment and prevention of chronic fatigue, exhaustion and/or exertional intolerance, preferably said PDE7 inhibitory compound inhibits the enzymatic activity of PDE7 (PDE7A, PDE7B, or PDE7A and PDE7B) at an IC50<50 μM, preferrably at an IC50≤1 μM, more preferred at an IC50 of from 0.1 to 600 nM, in particular preferred at an IC50 of from about 0.2 to about 100 nM, and further in particular preferred at an IC50 of from about 1 to about 100 nM.
